Humanized mice (target-specific)

Browse our catalog of target-specific humanized mouse models. Search by gene, model, or biological pathway to quickly find the model relevant to your research.

Typical applications of target-specific humanized mice

Target-specific humanized mouse models are used to support in vivo evaluation of biologics and immune-modulating therapies, by enabling physiologically relevant assessment of human targets in a murine system.

These models are commonly used for:

  • In vivo efficacy studies of antibodies and biologics
  • Target engagement and immune pathway validation
  • PK/PD and dose–response analyses
  • Translational evaluation of immuno-oncology strategies
No results
show more
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
1226 models available

Filter with any keyword

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Find your

Humanized mice (target-specific)

Select a model
Select by pathway & biological process
Reset filter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

genO-hCCR8/hCCL1

Double-humanized genO-hCCR8/hCCL1 immunocompetent mice enable the efficacy assessment of anti-CCR8 and CCL1 compounds.

Chemokine
genO-hCCR8/hCCL1

genO-hCD137

genO‑hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137.

CD137
ICP (single-target)
Immune checkpoint
genO-hCD137

genO-hCD28

The genO‑hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD28
ICP (single-target)
T-cell engager
genO-hCD28

genO-hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)
genO-hCD39

genO-hCD3ε

genO‑hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

T-cell engager
CD3
genO-hCD3ε

genO-hCD3ε/hCD28

genO‑hCD3ε/hCD28 immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

CD3
CD28
T-cell engager
genO-hCD3ε/hCD28

genO-hCD4

The humanized genO‑hCD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

CD4
Inflammation
T-cell receptor
genO-hCD4

genO-hCD47/hSIRPα

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the efficacy assessment of anti-CD47/SIRPα.

CD47
SIRPα
ICP (multi-target)
genO-hCD47/hSIRPα

genO-hCTLA-4

The genO‑hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
ICP (single-target)
genO-hCTLA-4

genO-hCTLA-4/hLAG3

The genO‑hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)
genO-hCTLA-4/hLAG3

genO-hFcγR

Preclinical humanized Fc-gamma receptor (genO‑hFcγR) model enabling the assessment of Fc receptor pathways targeted therapies.

FcgR
Fc receptor
genO-hFcγR

genO-hFcγR/hFcRn

Double-humanized genO‑hFcγR/hFcRn mouse model to improve PK assessment of compounds with extended half-life through FcRn binders.

Fc receptor
PK/PD
genO-hFcγR/hFcRn

genO-hFcγR/hIgG1

Double-humanized genO-hFcγR/hIgG1 mouse model to improve the tolerability to human IgG1 therapeutic antibodies.

Fc receptor
ICP (multi-target)
Immune checkpoint
genO-hFcγR/hIgG1

genO-hGITR

The genO‑hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)
genO-hGITR

genO-hGITR/hGITRL

The genO‑hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)
genO-hGITR/hGITRL

genO-hGLP-1R

Preclinical genO‑hGLP-1R model for assessment of agents targeting human GLP-1R

GLP-1R
Metabolism
genO-hGLP-1R

genO-hICOS

The genO-hICOS mouse enables the in vivo efficacy assessment of anti-ICOS-targeting agents in fully immunocompetent mice.

Immune checkpoint
ICP (single-target)
Icos
genO-hICOS

genO-hIgE/hFcεR1

Use the genO‑hIgE/hFcεR1 mouse model to successfully screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases.

Inflammation
IgE
FceR1
Fc receptor
Allergy
genO-hIgE/hFcεR1

genO-hOX40

The genO-hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Immune checkpoint
OX40
ICP (single-target)
genO-hOX40

genO-hOX40/hICOS

The genO‑hOX40/hICOS mouse enables the in vivo efficacy assessment of compounds targeting the human immune checkpoint OX40 and/or ICOS in fully immunocompetent mice.

Immune checkpoint
ICP (multi-target)
Icos
OX40
genO-hOX40/hICOS

genO-hPD-1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

PD-1
Immune checkpoint
ICP (single-target)
genO-hPD-1

genO-hPD-1/hCTLA-4

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)
genO-hPD-1/hCTLA-4

genO-hPD-1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL
genO-hPD-1/hGITR/hGITRL

genO-hPD-1/hICOS

The genO‑hPD‑1/hICOS mouse enables the in vivo efficacy assessment of compounds targeting the human immune checkpoint PD-1 and/or ICOS in fully immunocompetent mice.

Immune checkpoint
PD-1
ICP (multi-target)
Icos
genO-hPD-1/hICOS

genO-hPD-1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
PD-1
Lag3
ICP (multi-target)
genO-hPD-1/hLAG3

genO-hPD-1/hPD-L1

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)
genO-hPD-1/hPD-L1

genO-hPD-1/hTIM3

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)
genO-hPD-1/hTIM3

genO-hPD-1/hVISTA

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)
genO-hPD-1/hVISTA

genO-hSA/hFcRn

Double humanized genO‑hSA/hFcRn mouse model as a cutting-edge platform for preclinical development of hSA (hALB) and FcRn-oriented therapeutics.

HSA
PK/PD
Fc receptor
genO-hSA/hFcRn

genO-hSA/hFcRn-RAG1KO

This upgraded, immunocompromised RAG1-/- version of our genO-hSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

HSA
PK/PD
Fc receptor
KO-Rep-Mix
genO-hSA/hFcRn-RAG1KO

genO-hSTING

The genO‑hSTING mouse enables the in vivo assessment of agents and therapies targeting the human STING in fully immunocompetent mice.

STING
cGAS-STING pathway
genO-hSTING

genO-hTFRC

The fully immunocompetent genO‑hTFRC mouse model enables in vivo efficacy assessment and profiling of compounds targeting human TFRC (CD71, TfR1) and aiming to deliver therapeutic agents through the blood brain barrier.

TFRC
Drug shuttling
genO-hTFRC

genO-hTFRC/hFcγR

Double-humanized genO-hTFRC/hFcγR mouse model to improve biodistribution and enable drug shuttling through the blood-brain barrier (BBB).

FcgR
Fc receptor
TFRC
Drug shuttling
genO-hTFRC/hFcγR

genO-hTFRC/hSA/hFcRn

Triple-humanized genO-hTFRC/hSA/hFcRn mouse model for PK assessment of drugs aiming to cross the blood-brain barrier (BBB).

ICP (multi-target)
PK/PD
Immune checkpoint
TFRC
Drug shuttling
genO-hTFRC/hSA/hFcRn

genO-hTNF-α

The genO‑hTNF-α model provides new opportunities for assessment of anti-TNF therapies.

Inflammation
TNF
Cytokine
genO-hTNF-α

genO-hVISTA

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)
genO-hVISTA

genO-hcGAS

The genO‑hcGAS mouse enables the in vivo assessment of agents and therapies targeting the cGAS–STING cytosolic DNA sensing pathway in fully immunocompetent mice.

cGAS
cGAS-STING pathway
genO-hcGAS

genO-hcGAS/hSTING

The genO‑hcGAS/hSTING mouse enables the in vivo efficacy assessment of compounds targeting the human cGAS-STING pathway in fully immunocompetent mice.

Immune checkpoint
ICP (multi-target)
cGAS
cGAS-STING pathway
STING
genO-hcGAS/hSTING

genO-panhCD3

genO‑panhCD3 (humanized ε, δ and γ chains - hCD3edg) immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

T-cell engager
CD3
genO-panhCD3

genO-panhCD3/hCD137

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the efficacy assessment of anti-CD3 and CD137 compounds.

CD3
CD28
T-cell engager
Immune checkpoint
genO-panhCD3/hCD137

genO-panhCD3/hCD28

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the efficacy assessment of anti-CD3 and CD28 compounds.

CD3
CD28
T-cell engager
Immune checkpoint
genO-panhCD3/hCD28

Discover our customized models

Learn  more

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results
No results
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe